Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07784296
NCT07784296RecruitingNot Applicable

A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension

Hanmi Pharmaceutical Company Limited1 site in 1 country3,500 target enrollmentStarted: March 19, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
3,500
Locations
1
Primary Endpoint
The change in Systolic Blood Pressure (SBP) relative to baseline
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Korean patients aged 19 years or older diagnosed with hypertension
  • •Individuals newly diagnosed with hypertension or currently taking a single antihypertensive drug
  • •Individuals for whom administration of Amoprel tablets has been determined based on the researcher's medical judgment
  • •Individuals who have heard an explanation of this study and have voluntarily given written consent to participate in the study

Exclusion Criteria

  • •Individuals falling under the contraindications listed in the precautions for use of Amoprel Tab. or Amozartan Plus Tab.
  • •Pregnant women, women who may be pregnant, and nursing mothers
  • •Individuals currently participating in an interventional study
  • •Individuals deemed unsuitable for participation in this study by the researcher for other reasons

Outcomes

Primary Outcomes

The change in Systolic Blood Pressure (SBP) relative to baseline

Time Frame: the 6-month time

Secondary Outcomes

  • effectiveness of sequential triple combination therapy (amlodipine/losartan/chlorthalidone)(2, 4, 6 months)
  • Prescription patterns of a triple-therapy-based stepwise treatment strategy(2, 4, 6 months)
  • safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone)(2, 4 , 6 months)

Investigators

Sponsor
Hanmi Pharmaceutical Company Limited
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Study to characterize the efficacy and performance of the 100% Silicone Foley Balloon Catheter 2-way
CTRI/2024/01/061801Sterimed Group30
Completed
Not Applicable
Multicenter Study on the Use of a Collagen-based Hydrogel for the Treatment of 153 Periodontal Pockets in 38 Adults With Generalized Stage III PeriodontitisPeriodontitis
NCT07592377Bioteck S.p.A.38
Not yet recruiting
Not Applicable
Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer
NCT07308379Fudan University1,200
Recruiting
Not Applicable
A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab
NCT07487480Second Affiliated Hospital, School of Medicine, Zhejiang University60
Not yet recruiting
Phase 4
Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT)
NCT07481656Anhui Provincial Hospital160